Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming the healthcare sector as a whole. This time last year, the biotech ...

Vertex Pharmaceuticals (VRTX) shares soared 5.3% in the last trading session to close at $461.68. The move was backed by solid volume with far more shares changing hands than in a normal session.

Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of $540.00. The company’s shares closed ...

Our analysis of options history for Vertex Pharmaceuticals VRTX revealed 10 unusual trades. Delving into the details, we found 20% of traders were bullish, while 80% showed bearish tendencies.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

VRTX is a global biotechnology company that focuses on developing ... It provides sequencing and array-based instruments and consumables, whole-genome sequencing kits, genotyping, NIPT, and product ...

As of January 27 at 12:33:19 PM EST. Market Open.

For those who typically order takeout, meal kits may add more nutritional value to your day. If you are a TV dinner family more nights out of the week than you would like, using a meal kit can ...

The U.S. Food and Drug Administration approved a new prescription-strength pain reliever from Vertex Pharmaceuticals on Jan. 30, 2025. Journavx is a non-opioid drug that prevents peripheral nerves ...

Images, and the devices that capture them, are my focus. I've covered cameras at PCMag for the past 13 years, which has given me a front row seat for the DSLR to mirrorless transition, the ...